Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis

British Journal of Clinical Pharmacology

Volumn 59, Issue 3, 2005, Pages 310-313

  Van Kan, H J M ^a   Groeneveld, C J ^b   Kalmijn, S ^b   Spieksma, M ^a   Van Den Berg, L H ^b   Guchelaar, H J ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CYP1A2; Metabolism; Neuromuscular disease; Pharmacokinetics; Riluzole

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; PARAXANTHINE; RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTICONVULSANTS; CAFFEINE; CYTOCHROME P-450 CYP1A2; FEMALE; HUMANS; MALE; MIDDLE AGED; RILUZOLE; THEOPHYLLINE;

EID: 15244343148     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02233.x     Document Type: Article

References (19)

1. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585-91.
2. Lacomblez L, Bensimon G, Leigh PN, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-11. Neurology 1996; 47: S242-S250.
3. Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J. Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport 1994; 5: 1012-4.
4. Estevez AG, Stutzmann JM, Barbeito L. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur J Pharmacol 1995; 280: 47-53.
5. Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995; 65: 643-51.
6. Bruno R, Vivier N, Montay G, et al. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin Pharmacol Ther 1997; 62: 518-26.
7. Le Liboux A, Lefebvre P, Le Roux V, et al. Single- and multiple-dose pharmacokinetics of riluzole in white subjects. J Clin Pharmacol 1997; 37: 820-7.
8. Wokke J. Riluzole. Lancet 1996; 348: 795-9.
9. Anonymous. Rilutek 50 mg, Summary of Product Characteristics. European Public Assessment Report, Revision 8, 13/12/2002. European Agency for the Evaluation of Medicinal Products.
10. Sanderink GJ, Bournique B, Stevens J, Petry M, Martinet M. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther 1997, 2002; 282: 1465-72.
11. Groeneveld GJ, Van Kan HJ, Torano JS, et al. Inter- and intra-individual variability of riluzole serum concentrations in patients with ALS. J Neurol Sci 2001; 191: 121-5.
12. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53: 503-14.
13. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4: 109-16.
14. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-9.
15. Koch JP, ten Tusscher GW, Koppe JG, Guchelaar HJ. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CVP1A2 phenotyping. Biomed Chromatogr 1999; 13: 309-14.
16. Van Kan HJM, Spieksma M, Sastre Torano J, Guchelaar HJ. A validated assay to monitor riluzole serum concentrations in patients with amyotrophic lateral sclerosis. Biomed Chromatogr 2004; 18 (9): 721-724.
17. Proost JH, Meijer DKF. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22: 155-63.
18. Groeneveld GJ, Van Kan HJ, Kalmijn S, Veldink JH, Guchelaar HJ, Wokke JH, Van den Berg LH. Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms. Neurology 2003; 61: 1141-3.
19. Mahmood I. Impact of random and fixed (optimal) sampling approach on the Bayesian estimation of clearance. Int J Clin Pharmacol Ther 2003; 41: 392-6.